E2F transcription factors and cancer

Clinical and Translational Oncology

Volumn 3, Issue 5, 2001, Pages 241-249

  Piulats, Jaume ^a   Tarrasón, Gema ^a  

^a Laboratorio de Bioinvestigación   (Spain)

Author keywords

Apoptosis.; Cancer; E2F

Indexed keywords

EID: 84865402763     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Avantaggiati ML. Molecular horizons of cancer therapeutics 11th Pezcoller Symposium. Biochim Biophys Acta 2000; 1.470: R49-R59.
2. Stiewe T, Pützer B. Role of the p53-homologue p73 in E2F-1 - induced apoptosis. Nature Genetics 2000; 26: 464-469.
3. Brooks G, La Thange NB. The cell cycle and drug discovery: the promise and the hope Drug Discovery Today 1999; 4 (10): 455-464.
4. Murray A. Cell cycle checkpoints. Curr Opin Cell Biol 1994; 6: 872-876.
5. Guo M, Hay B. Cell proliferation and apoptosis. Curr Opin Cell Biol 1999; 11: 745-752.
6. Hartwell L, Kastan M. Cell cycle control and cancer. Science 1994; 266: 1.821-1.828.
7. Peters G, Bates S, Parry D. The D-cyclins, their kinases and their inhibitors. In: Latchman DS, ed. Apoptosis and CellCycle Control in Cancer. London: BIOS Scientific Publishers, 1996; 37-53.
8. Lohka MJ, Hayes MK, Maller JL. Purification of maturation- promoting factor, an intracellular regulator of early mitotic events. Proc Natl Acad Sci USA 1988; 85: 3.009-3.013.
9. Dunphay W, Brisuela L, Beach D, Newport J. The xenopus cdc 2 protein is a component of MPF, a cytoplasmic regulator of mitosis. Cell 1988; 54: 423- 431.
10. Gautier J, Solomon MJ, Booher RN, Bazan JF, Kirschner MW. cdc 25 is a specific tyrosine phosphatase that directly activates p34cdc 2. Cell 1991; 67: 197-211.
11. Dunphy WG. The decision to enter mitosis. Trends Cell Biol 1994; 4: 202-207
12. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001; 353: 417-439.
13. Graña X, Garriga J, Mayol X. Role of the retinoblastoma protein family, pRb, p107 and p130 in the negative control of cell growth. Oncogene 1998; 17: 3.365-3.383.
14. Thullberg M, Bartkova J, Khan S, et al. Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors. FEBS Letters 2000; 470: 161-166.
15. Helin K, Lees JA, Vidal M, Dyson N, Harlow E, Fattaey A. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 1992; 70: 337-350.
16. Kaelin WG Jr, Sellers WR, DeCaprio JA, et al. Expression cloning of a cDNA encoding a retinoblastoma binding protein with E2F-like properties. Cell 1992; 70: 351-364.
17. Ivey-Hoyle M, Conroy R, Huber H, Goodhart P, Oliff A, Heinbrook DC. Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F. Mol Cell Biol 1993; 13: 7.802-7.812.
18. Lees JA, Saito M, Vidal M, et al. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 1993; 13: 7.813-7.825.
19. Beijersbergen RL, Kerkhoven RM, Zhu L, Carlee L, Voorhoeve PM, Bernards R. E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes & Dev 1994; 8: 2.680-2.690.
20. Ginsberg D, Vairo G, Chittenden T, et al. E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes & Dev. 8: 2.665- 2.679.
21. Sardet C, Vidal M, Cobrinik D, et al. E2F-4 and E2F-5, two novel members of the E2F family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci 1995; 92: 2.403-2.407.
22. Hijmans EM, Voorhoeve RL, Beijersbergen LV, Bernards R. E2F-5 a new E2F family member that interacts with p130 in vivo. Mol Cell Biol 1995; 15: 3.082-3.089.
23. Morkel M, Wenkel J, Bannister AJ, Kouzarides T, Hagemeier C. An E2F-like repressor of transcription. Nature 1997; 390: 567-568.
24. Cartwright P, Müller H, Wagener C, Holm K, Helin K. E2F-6: A novel member of the E2F family is an inhibitor of E2F-dependent transcription. Oncogene 1998; 16 (in press).
25. Trimarchi JM, Fairchild B, Verona R, Moberg K, Andon N, Lees JA. E2F-6, a member of the E2F family tha can behave as a transcriptional repressor. Proc Natl Acad Sci 1998; 95: 2.850-2.855.
26. Girling R, Partridge JF, Bandara LR, et al. A new component of the transcription factor DRTF1/E2F. Nature 1993; 362: 83-87.
27. Wu CL, Zukerberg LR, Ngwu C, Harlow E, Lees JA. In vivo association of E2F and DP family proteins. Mol Cell Biol 1995; 15:2.536-2.546.
28. Kitagawa M, Higashi H, Suzuki-Takahashi I, et al. Phosphorylation of E2F-1 by cyclin A-cdk2. Oncogene 1995; 10: 229-236.
29. Krek W, Ewen ME, Shirodkar S, Arany ZZ, KaelinWG, Livingston D. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 1994; 78: 161-172.
30. Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica- Worms H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol 1994; 14: 8.420- 8.431.
31. Lindeman GJ, Gaubatz S, Livingston DM, Ginsberg D. The subcellular localization of E2F-4 is cellcycle dependent. Proc Natl Acad Sci 1997; 94: 5.095-5.100.
32. Magae J, Wu C-L, Illenye S, Harlow E, Heintz NH. Nuclear localization of DP and E2F transcription factors by heterodimeric partners and retinoblastoma protein family members. J Cell Sci 1996; 109: 1.717-1.726.
33. Verona R, Moberg K, Estes S, Starz M, Vernon JP, Lees JA. E2F activity is regulated by cell-cycledependent changes in subcellular localization. Mol Cell Biol 1997; 17: 7.268-7.282.
34. Karlseder J, Rotheneder H, Wintersberger E. Interaction of Sp 1 with the growth- and cell cycle-regulated transcription factor E2F. Mol Cell Biol 1996; 16:1.659-1.667.
35. Lin S-Y, Black AR, Kostic D, Pajovic S, Hoover CN, Azizkhan JC. Cell cycle-regulated association of E2F- 1 and Sp 1 is related to their functional interaction. Mol Cell Biol 1996; 16: 1.668-1.675.
36. Sardet C, LeCam L, Fabbrizio E, Vidal M. E2F and the retinoblastoma protein family. In: Ghysdael J, Yaniv M, eds. Oncogenes as transcriptional regulators. Berlin, Germany: Birkhauser Verlag, 1997; 2: 1-63.
37. Gaubatz S, Wood JG, Livingston DM. Unusual proliferation arrest and transcriptional control properties of a newly discovered E2F family member, E2F-6. Proc Natl Acad Sci USA 1998; 95: 9.190- 9.195.
38. He Y, Armanious MK, Thomas MJ, Cress WD. Identification of E2F-3B, an alternative form of E2F- 3 lacking a conserved N-terminal region. Oncogene 2000; 13, 19 (30): 3.422-3.433.
39. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S, Lees JA. E2f3 is critical for normal cellular proliferation Genes. Dev 2000; 14: 690-703.
40. Muller H, Helin K. The E2F transcription factors: key regulators of cell proliferation. Biochim Biophys Acta 2000; 1.470: M1-M12.
41. Kusek JC, Greene RM, Nugent P, Pisano MM. Expression of the E2F family of transcription factors during murine development. Int J Dev Biol 2000; 44 (3): 267-277.
42. Marzio G, Wagener C, Gutiérrez MI, Cartwright P, Helin K, Giacca M. E2F family members are differentially regulated by reversible acetylation. J Biol Chem 2000; 275 (15): 10.887-10.892.
43. Campanero MR, Armstrong MI, Flemington EK. CpG methylation as a mechanism for the regulation of E2F activity. Proc Natl Acad Sci USA 2000; (12): 6.481-6.486.
44. Field S, Tsai F, Kuo F, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549-561.
45. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson N. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537-548.
46. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
47. Weinberg RA. E2F and cell proliferation: a world turned upside down. Cell 1996; 85: 457-459.
48. Yamasaki L. Balancing proliferation and apoptosis in vivo: the goldilocks theory of E2F/DP action. Biochim Biophys Acta 1999; 1423: M9-M15.
49. Bates S, Phillips AC, Clark PA, et al. p14ARF links the tumour suppressors RB and p53. Nature 1998; 395: 124- 125.
50. Martelli F, Hamilton T, Silver DP, et al. p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA 2001; 98 (8): 4.455-4.460.
51. Carner A, Hudson JD, Price CM, Beach DH. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2000; 2 (3): 148-155.
52. Irwin M, Marin MC, Phillips AC, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000; 407: 645-648.
53. Soengas M, Lowe S. p53 and p73: seeing double? Nat Genet 2000; 26: 391-392.
54. Lissy N, Davis P, Irwin M, Kaelin W, Dowdy S. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 2000; 407: 642-644.
55. Nakamura et al.5 5 (REF 54 Rabbani).
56. Saito M, Helin K, Valentine MB, et al. Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics 1995; 25 (1): 130-138.
57. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer 1999; 81 (4): 535-538.
58. Souza RF, Yin J, Smolinski KN, et al. Cancer Research, Vol 57, Issue 12 2350-2353, Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors.
59. Matsubara N, Yoshitaka T, Matsuno T, et al. Multiple tumors and a novel E2F-4 mutation. A case report. Digestion 2000; 62 (2-3): 213-216.
60. Woo DK, Lee WA, Kim YI, Kim WH. Microsatellite instability and alteration of E2F-4 gene in adenosquamous and squamous cell carcinomas of the stomach. Pathol Int 2000;50 (9): 690-695.
61. Komatsu N, Takeuchi S, Ikezoe T, et al. Mutations of the E2F4 gene in haematological malignancies having microsatellite instability. Blood 2000; 95 (4): 1.509-1.510.
62. Schwemmle S, Pfeifer GP. Genomic structure and mutation screening of the E2F4 gene in human tumors. Int J Cancer 20001; 86 (5): 672-677.
63. Polanowska J, Le Cam L, Orsetti B, et al. Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors. Genes Chromosomes Cancer 2000; 28 (1): 126-130.
64. Rabbani F, Richon VM, Orlow I, et al. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst 1999; 91; 874-881.
65. Rabbani F, Cordon-Cardo C. Mutation of cell cycle regulators and their impact on superficial bladder cancer. Urol Clin North Am 2000; 27 (1): 83-102.
66. Moller MB, Kania PW, Ino Y, et al. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia 2000; 14 (5): 898-904.
67. Yasui W, Fujimoto J, Suzuki T, et al. Expression of cell-cycle-regulating transcription factor E2F-1 in colorectal carcinomas. Pathobiology 1999; 67 (4): 174-179.
68. Volm M, Koomagi R, Rittgen W. Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int J Cancer 1998; 79 (3): 294-299.
69. DeMuth JP, Jackson CM, Weaver DA, et al. The gene expression index c-myc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells. Am J Respir Cell Mol Biol 1998;19(1):18-24.
70. Zhang SY, Liu SC, Johnson DG, Klein-Szanto AJ. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res 2000; 60 (21): 5.972-5.976.
71. Gorlick R, et al. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 1998; 16: 1.465- 1.469.
72. Banerjee, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino Jr. Role of E2F-1 in chemosensitivity. Cancer Res 1998; 58: 4.292-4.296.
73. Banerjee D, Gorlick R, Liefshitz A, et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res 2000; 60 (9): 2.365-2.367.
74. Halaban R, Cheng E, Smicun Y, Germino J. Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med 2000; 191 (6): 1.005-1.016.
75. Halaban R. Melanoma cell autonomous growth: the Rb/E2F pathway. Cancer Metastasis Rev 1999; 18 (3): 333-343.
76. Wang A, Schneider-Broussard R, Kumar AP, MacLeod MC, Johnson DG. Regulation of BRCA1 expression by the Rb-E2F pathway. J Biol Chem 2000; 275 (6): 4.532-4.536.
77. Lee RJ, Albanese C, Fu M, et al. Cyclin D1 is required for transformation by activated Neu and is ind u c e d through an E2F-dependent signalling pathway. Mol Cell Biol 2000; 20 (2): 672-683.
78. Brizuela L, Gyuris J, Manzoni M. Cyclin-dependent kinases and their regulators as potential targets for anticancer therapeutics. In: Bronchua MH, Foote MA, Peters WP, Robinson MO, eds. Principles of molecular oncology. Totowa NJ: Humana Press, 2000; 197- 236.
79. Fueyo J, Gómez-Manzano C, Yung WK, et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 1998; 4: 685-690.
80. Liu TJ, Wang M, Breau RL, et al. Apoptosis induction by E2F-1 via adenoviral-mediated gene transfer results in growth suppression of head and neck squamous cell carcinoma cell lines. Cancer Gene Ther 1999; 6: 163-171.
81. Senderowicz AM. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 2001; 15(1): 1-9.
82. Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Invest Drugs 2000; 9 (12): 2.903- 2.911.
83. Brotherton DH, Dhanaraj V, Wick S, et al. Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature 1998; 395 (6.699): 244-250.
84. Wang QM, Feinman R, Kashanchi F, et al. Changes in E2F binding after phenylbutyrate-induced differentiation of Caco-2 colon cancer cells. Clin Cancer Res 2000; 6: 2.951-2.958.
85. M orishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92 (13): 5.855-5.859 86.
86. Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000; 106 (9): 1.071-1.075.
87. Kawauchi M, Suzuki J, Morishita R, et al. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res 2000; 87 (11): 1.063-1.068.
88. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ. Longterm stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001; 121 (4): 714-722.
89. Aoki M, Morishita R, Ogihara T. Gene therapy for arteriosclerotic diseases. Nippon Rinsho 2001; 59 (1): 43-52.
90. Rutanen J, Rissanen TT, Kivela A, Vajanto I, Yla- Herttuala S. Clinical applications of vascular gene therapy. Curr Cardiol Rep 2001; 3 (1): 29-36.
91. Kawamura I, Morishita R, Tomita N, et al. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 1999; 6 (1): 91-97.
92. Chiang S-Y, Bruice T, Azizkhan J, Gawron L, Beerman T. Targeting E2F1-DNA complexes with microgonotropen DNA binding agents. Proc Natl Acad Sci USA 1997; 94: 2.811-2.816.
93. Cozzi P. A new class of cytotoxic DNA minor groove binders: alfa-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers. Farmaco 2001; 56 (1- 2): 57-65.
94. Putzer BM, Stiewe T, Crespo F, Esche H. Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy. Gene Ther 2000; 7 (15): 1.317- 1.325.
95. Dong YB, Yang HL, Elliott MJ, et al. Adenovirusmediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer 1999; 86 (10): 2.021-2.033.
96. Atienza C Jr, Elliott MJ, Dong YB, et al. Adenovirusmediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors. Int J Mol Med 2000; 6 (1): 55-63.
97. G ó mez-Manzano C, Fueyo J, Alameda F, Kyritsis AP, Yung WK. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int J Mol Med 1999; 3 (1): 81-85.
98. Yang HL, Dong YB, Elliott MJ, Liu TJ, McMasters KM. Caspase activation and changes in Bcl-2 family member protein expression associated with E2F-1- mediated apoptosis in human esophageal cancer cells. Clin Cancer Res 2000; 6 (4): 1.579-1.589.
99. Yang HL, Dong YB, Elliott MJ, et al. Adenovirusmediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells. Clin Cancer Res 1999; 5 (8): 2.242-2.250.
100. Fabbrizio E, Le Cam L, Polanowska J, et al. Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that funtiolally antagonize E2F activity. Oncogene 1999; 18: 4.357-4.363.
101. Bandara LR, Buck VM, Zamanian M, Johnston LH, La Thanguc NB. Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F. EMBO J 1993; 12: 4.317-4.324.
102. Mitlianga PG, Kyritsis AP, Gomez-Manzano C, et al. Co-expression of E2F-2 enhances the p53 anticancer effect in human glioma cells. Int J Oncol 2001; 18 (2): 343-347.